Observation On The Clinical Effect Of Du Moxibustion Combined With Mesalazine In The Treatment Of Ulcerative Colitis With Mild And Moderate Deficiency Of Spleen And Kidney Yang

Objective: To observe the clinical effect of Du moxibustion combined with Mesalazine for the treatment of patients with mild and moderate splenorenal Yang deficiency type Ulcerative Colitis,evaluate the efficacy and safety of this treatment regimen,explore the therapeutic effect of external medicine and traditional Chinese medicine(TCM)on Ulcerative Colitis,and provide a new idea for using TCM means to treat Ulcerative Colitis.Methods: A total of 76 patients with mild and moderate ulcerative colitis who were treated in our hospital from September 2020 to December2022 and were consistent with spleen-kidney Yang deficiency type(including elimination and shedding cases)were selected as research objects,and divided into experimental group and control group,with 38 cases in each group.The control group was given Du mesalazine orally,1.5g,twice a day;On this basis,the treatment group was given supervision Du moxibustion therapy,and the Du moxibustion of "eight scalao" was strengthened,once a week,for 8 weeks.Mayo score,total score of TCM syndromes,major TCM syndromes score(including diarrhea,abdominal pain,mucous,abscess and blood stostoes,cold appearance and cold limbs),minor TCM syndromes score(including waist and knee tenderness,poor food intake,abdominal distension),quality of life score (IBD-Q scale)and safety index before and after treatment were observed and compared.Statistical software SPSS26.0 was used to process and analyze the collected data,to judge the clinical effective rate,clinical remission rate,TCM syndrome efficacy,endoscopic response rate and mucosal healing rate of the two groups,and to evaluate the clinical efficacy and safety of the two groups of schemes.Results:(1)In this study,a total of 80 patients met the inclusion criteria.Affected by poor patient compliance and epidemic situation,6patients in the experimental group and 5 patients in the control group fell off during the study.The study was finally completed,with 34 patients in the experimental group and 35 patients in the control group,a total of69 patients.(2)Before treatment,there were no significant differences in age,gender,course of disease and severity of disease between the two groups(P>0.05).(3)In terms of clinical efficacy,the clinical effective rate of the experimental group was 79.4%,and that of the control group was 57.1%.The effective rate of the experimental group was better than that of the control group,and the difference was statistically significant(P<0.05).The clinical remission rate of the experimental group was 52.9%,and that of the control group was 28.6%.The effective rate of the experimental group was better than that of the control group,and the difference was statistically significant(P<0.05).(4)In terms of TCM syndrome score,there was no statistical significance in total TCM syndrome score and individual TCM syndrome score between the two groups before treatment(P>0.05);The total score of TCM syndrome and individual score of TCM syndrome in 2 groups after treatment were lower than before treatment(P<0.05);The total score of TCM syndrome in experimental group was significantly lower than that in control group(P<0.05);Compared with the scores of the main TCM syndromes,the scores of diarrhea,abdominal pain,mucous,pus and blood stool,cold shape and limb cold of the experimental group were significantly lower than those of the control group after treatment(P<0.05).Compared with the scores of minor syndroms of traditional Chinese medicine,the scores of lumbar and knee tenderness,poor food intake and abdominal distension of experimental group were significantly lower than those of control group after treatment(P<0.05).In terms of TCM syndromes,the total effective rate of the experimental group was 94.1%.The control group was 62.9%,and the experimental group was better than the control group(P<0.05).(5)In terms of endoscopic response rate and mucosal healing rate,the endoscopic response rate of experimental group was 55.9%,and that of control group was 28.5%,which was better in experimental group than in control group(P<0.05).The healing rate of mucosal healing was 38.2% in experimental group and 31.4% in control group,and there was no significant difference between the two groups(P>0.05).(6)There was no significant difference in the quality of life score between the two groups before treatment(P>0.05),and the score of the experimental group was significantly higher than that of the control group after treatment(P<0.05).(7)In terms of safety evaluation,during the study period,patients in both groups had no obvious discomfort symptoms,no adverse events were recorded,and no obvious abnormalities were found in electrocardiogram,blood routine,liver and kidney function tests before and after treatment.Conclusion: Both Du moxibustion and mesalazine can improve the clinical symptoms of mild and moderate ulcerative colitis with spleen-kidney Yang deficiency.In the treatment of mild and moderate ulcerative colitis with spleen and kidney Yang deficiency,Du moxibustion combined with mesalazine has better efficacy and safety than that of Western medicine alone in terms of improving clinical therapeutic effect,inducing disease remission,improving TCM symptoms,improving endoscopic intestinal manifestations,and improving patients’ quality of life.